[go: up one dir, main page]

CY1116671T1 - Πενταειδικο αντισωμα - Google Patents

Πενταειδικο αντισωμα

Info

Publication number
CY1116671T1
CY1116671T1 CY20151100768T CY151100768T CY1116671T1 CY 1116671 T1 CY1116671 T1 CY 1116671T1 CY 20151100768 T CY20151100768 T CY 20151100768T CY 151100768 T CY151100768 T CY 151100768T CY 1116671 T1 CY1116671 T1 CY 1116671T1
Authority
CY
Cyprus
Prior art keywords
antibody
pentecostal
gro
present
ena
Prior art date
Application number
CY20151100768T
Other languages
English (en)
Inventor
Stephanie Jane Clegg
Eric Dobrzynski
Jonathan H Ellis
Volker Germaschewski
Alexis Paul Godillot
Zdenka Ludmila Jonak
Alan P Lewis
John R White
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CY1116671T1 publication Critical patent/CY1116671T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με αντίσωμα που έχει πολλαπλές εξειδικεύσεις. Συγκεκριμένα, το αντίσωμα της παρούσας εφεύρεσης δεσμεύεται (αλληλεπιδρά) με ανθρώπινες IL-8, Gro-α, Gro-β, Gro-γ, και ΕΝΑ-78.
CY20151100768T 2007-04-17 2015-09-01 Πενταειδικο αντισωμα CY1116671T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91222907P 2007-04-17 2007-04-17
US4413208P 2008-04-11 2008-04-11
EP08745931.9A EP2146745B1 (en) 2007-04-17 2008-04-16 penta-specific antibody

Publications (1)

Publication Number Publication Date
CY1116671T1 true CY1116671T1 (el) 2017-03-15

Family

ID=39872910

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100768T CY1116671T1 (el) 2007-04-17 2015-09-01 Πενταειδικο αντισωμα

Country Status (29)

Country Link
US (3) US8496932B2 (el)
EP (1) EP2146745B1 (el)
JP (1) JP5441885B2 (el)
KR (1) KR101560841B1 (el)
CN (1) CN101687035B (el)
AU (1) AU2008243049B2 (el)
BR (1) BRPI0810250A8 (el)
CA (1) CA2684626C (el)
CL (1) CL2008001071A1 (el)
CO (1) CO6251323A2 (el)
CR (1) CR11116A (el)
CY (1) CY1116671T1 (el)
DK (1) DK2146745T3 (el)
DO (1) DOP2009000236A (el)
EA (1) EA024621B1 (el)
ES (1) ES2547475T3 (el)
HR (1) HRP20150937T1 (el)
HU (1) HUE027584T2 (el)
IL (1) IL201440A (el)
MA (1) MA31310B1 (el)
MX (1) MX2009011153A (el)
MY (1) MY150525A (el)
NZ (1) NZ580239A (el)
PE (1) PE20090302A1 (el)
PL (1) PL2146745T3 (el)
PT (1) PT2146745E (el)
SI (1) SI2146745T1 (el)
TW (1) TWI473815B (el)
WO (1) WO2008130969A2 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2783563A1 (en) * 2009-12-07 2011-06-16 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
US20120315267A1 (en) * 2010-02-09 2012-12-13 Glaxosmithkline Llc Novel uses
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
US9605058B2 (en) 2012-05-01 2017-03-28 Glaxosmithkline Llc Antibodies against the CXC-ELR family of chemokines
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
WO2014030728A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 FcγRIIb特異的Fc領域改変体
EP2970445A4 (en) 2013-03-12 2017-02-22 Decimmune Therapeutics Inc. Humanized anti-n2 antibodies
US9290570B2 (en) 2013-03-15 2016-03-22 Eli Lilly And Company Pan-ELR+ CXC Chemokine Antibodies
TWI612059B (zh) * 2013-03-15 2018-01-21 美國禮來大藥廠 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
EP2796875B8 (en) * 2013-04-23 2020-11-25 Albert-Ludwigs-Universität Freiburg Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis
AU2014267171A1 (en) * 2013-05-17 2015-12-10 Centre National De La Recherche Scientifique (Cnrs) Anti-CXCL1, CXCL7 and CXCL8 antibodies and their applications
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
TWI887899B (zh) 2018-03-15 2025-06-21 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體之用途
CA3092695A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Human pd-l2 antibodies and methods of use therefor
EP3768726B1 (en) 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
AU2019239568B2 (en) * 2018-03-23 2025-09-11 Board Of Regents, The University Of Texas System Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor
JP7551750B2 (ja) * 2019-12-05 2024-09-17 シージェン インコーポレイテッド 抗αｖβ６抗体及び抗体薬物コンジュゲート
TW202206457A (zh) * 2020-04-24 2022-02-16 美商美國禮來大藥廠 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
US20220080044A1 (en) * 2020-09-14 2022-03-17 National Yang-Ming University Method for preventing or treating peripheral arterial occlusive disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE913192A1 (en) * 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
US6448379B1 (en) * 1993-09-14 2002-09-10 Chiron Corporation IL8 inhibitors
PT833911E (pt) * 1995-06-07 2004-09-30 Ortho Mcneil Pharm Inc Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
AR030753A1 (es) * 2000-09-25 2003-09-03 Smithkline Beecham Corp Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
EP1326897A2 (en) * 2000-10-13 2003-07-16 Biogen, Inc. Humanized anti-lt-beta-r antibodies
EP1414860B1 (en) * 2001-04-26 2009-12-30 Dako Denmark A/S Anti-glycated hemoglobin pan-specific monoclonal antibody
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
ATE527278T1 (de) * 2002-12-16 2011-10-15 Genmab As Humane monoklonale antikörper gegen interleukin 8 (il-8)
AU2003303543A1 (en) * 2002-12-26 2004-07-29 Chugai Seiyaku Kabushiki Kaisha Agonist antibody against heteroreceptor
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
ZA200710496B (en) * 2005-06-02 2009-04-29 Astrazeneca Ab Antibodies directed to CD20 and used thereof
CN101612399B (zh) * 2005-06-17 2013-11-27 英克隆有限责任公司 用作治疗继发性骨肿瘤的抗PDGFRα抗体
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains

Also Published As

Publication number Publication date
EA200970954A1 (ru) 2010-08-30
JP2010524469A (ja) 2010-07-22
TWI473815B (zh) 2015-02-21
US20110229475A1 (en) 2011-09-22
EA024621B1 (ru) 2016-10-31
MA31310B1 (fr) 2010-04-01
HUE027584T2 (en) 2016-11-28
MY150525A (en) 2014-01-30
US20140010807A1 (en) 2014-01-09
PT2146745E (pt) 2015-10-14
IL201440A (en) 2016-08-31
PE20090302A1 (es) 2009-04-03
WO2008130969A2 (en) 2008-10-30
KR20100020946A (ko) 2010-02-23
BRPI0810250A2 (pt) 2014-10-14
US8496932B2 (en) 2013-07-30
HRP20150937T1 (hr) 2015-10-09
DK2146745T3 (en) 2015-09-14
CA2684626A1 (en) 2008-10-30
CN101687035B (zh) 2013-06-12
PL2146745T3 (pl) 2015-11-30
EP2146745A2 (en) 2010-01-27
AU2008243049A1 (en) 2008-10-30
TW200906855A (en) 2009-02-16
BRPI0810250A8 (pt) 2017-02-21
CA2684626C (en) 2014-11-04
EP2146745B1 (en) 2015-06-17
US8828384B2 (en) 2014-09-09
WO2008130969A3 (en) 2008-12-18
KR101560841B1 (ko) 2015-11-11
CL2008001071A1 (es) 2009-05-22
JP5441885B2 (ja) 2014-03-12
CO6251323A2 (es) 2011-02-21
EP2146745A4 (en) 2011-11-30
HK1136970A1 (en) 2010-07-16
MX2009011153A (es) 2009-10-30
CR11116A (es) 2010-03-22
DOP2009000236A (es) 2009-11-15
ES2547475T3 (es) 2015-10-06
AU2008243049B2 (en) 2011-04-21
US20080262203A1 (en) 2008-10-23
SI2146745T1 (sl) 2015-10-30
IL201440A0 (en) 2010-06-16
CN101687035A (zh) 2010-03-31
NZ580239A (en) 2012-07-27

Similar Documents

Publication Publication Date Title
CY1116671T1 (el) Πενταειδικο αντισωμα
CL2013003090A1 (es) Polipeptido que comprende una primera secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17f, il17-a/f, pero no a il-17a, y una segunda secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17a, il-17f y il17-a/f; composicion farmaceutica que lo comprende; y su uso.
CY1124472T1 (el) Κατασκευασματα διειδικων αντισωματων που δεσμευουν dll3 και cd3
CR11783A (es) Molecula de union al antigeno capaz de unirse repetidamente a dos o mas moleculas de antigeno
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
CR20110400A (es) Proteinas de enlace al receptor cgrp humano
CY1119890T1 (el) Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1
ES2684475T3 (es) Proteínas que se unen a beta amiloide
CR20150437A (es) Construcciones de anticuerpos para cdh19 y cd3
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
CR11298A (es) Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano
ECSP10010297A (es) Anticuerpos bivalentes biespecíficos
ECSP10010270A (es) Anticuerpos bivalentes biespecíficos
CY1118710T1 (el) Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης
EA200900492A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
CR20120210A (es) Proteínas de enlace al antigeno il-23 humanas
BRPI0816680A2 (pt) Gerar e comunicar informações de identificação de origem pra habilitar comunicações confiáveis.
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
CY1118244T1 (el) Αντισωματα κατα της il-25
CL2009001258A1 (es) Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina.
NO20091064L (no) Antistoffer mot IL-17A
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
CR11282A (es) Proteinas enlazadas al antigeno de celula de cepa mcdonough de felino humanas
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης